Phase Ia/Ib multicenter investigator initiated trial of Mogamulizumab for advanced or recurrent cancer

Trial Profile

Phase Ia/Ib multicenter investigator initiated trial of Mogamulizumab for advanced or recurrent cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Mogamulizumab (Primary)
  • Indications Gastric cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 18 Oct 2017 Results (n=6) assessing response against chemotherapy before and after mogamulizumab treatment in 6 advanced lung cancer patients who were enrolled in the clinical trial, were presented at the 18th World Conference on Lung Cancer.
    • 20 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 16 Feb 2016 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top